It is a small molecule protein tyrosine kinase inhibitor that competitively binds to the ATP binding site on the BCR-ABL protein, thereby blocking the continuous phosphorylation of ABL kinase and its downstream molecules and inducing apoptosis in CML cells. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.